Superhemophobic Surfaces with Improved Hemocompatibility

Opportunity

Available for Licensing

IP Status

US Utility Patent Pending: US 15/954,943

Inventors

Arun Kota
Ketul Popat
Lakshmi Prasad

At A Glance
  • Current medical implant surfaces suffer from platelet adhesion / blood clotting
  • Researchers at CSU have created novel surfaces to reduce blood clotting
  • Market: med devices such as vascular stents, IVC filters, and cardiac occlusion devices
Licensing Director

Mandana Ashouri
Mandana.Ashouri@colostate.edu
970-491-7100

Reference No.: 17-049

Background

Titanium based implants have created a great deal of attention for their biocompatibility with many different tissues within the human body. However, when these implants come into contact with blood, platelet adhesion and activation occur, which may lead to further thrombosis and sometimes failure of these implants.

Technology Overview

Researchers at CSU have created superhemophobic surfaces (surfaces that are extremely repellent to blood). Specifically, a fluorinated titanium surface having a textured morphology of either a nanotube or nanoflower array.

Benefits

  • Significantly reduced platelet adhesion and activation
  • Formation of blood clot on superhemophobic surface is negligible

Last updated on October 7, 2019.